Within-subject variation of plasma resistin levels over a 1-year period

Clinical Chemistry and Laboratory Medicine

Volumn 45, Issue 7, 2007, Pages 899-902

  Weikert, Cornelia ^a   Westphal, Sabine ^b   Luley, Claus ^b   Willich, Stefan N ^c   Boeing, Heiner ^a   Pischon, Tobias ^a,c  

^a GERMAN INSTITUTE OF HUMAN NUTRITION   (Germany)

^b UNIVERSITY HOSPITAL MAGDEBURG   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Biomarker; Inflammation; Obesity; Reliability; Risk factor

Indexed keywords

RESISTIN;

ADULT; AGED; ANALYSIS OF VARIANCE; ARTICLE; BODY MASS; CALCULATION; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORRELATION COEFFICIENT; DATA ANALYSIS; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; RELIABILITY; STUDENT T TEST; WAIST HIP RATIO;

ADULT; AGED; BIOLOGICAL MARKERS; BODY MASS INDEX; COHORT STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; RESISTIN; RISK FACTORS; SEX CHARACTERISTICS; WAIST-HIP RATIO;

EID: 34447292306     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2007.148     Document Type: Article

References (28)

1. Kim KH, Lee K, Moon YS, Sul HS. A cysteine-rich adipose tissue-specific secretory factor inhibits adipocyte differentiation. J Biol Chem 2001;276:11252-6.
2. Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, et al. The hormone resistin links obesity to diabetes. Nature 2001;409:307-12.
3. Steppan CM, Lazar MA. The current biology of resistin. J Intern Med 2004;255:439-47.
4. Savage DB, Sewter CP, Klenk ES, Segal DG, Vidal-Puig A, Considine RV, et al. Resistin / Fizz3 expression in relation to obesity and peroxisome proliferator-activated receptor-gamma action in humans. Diabetes 2001;50:2199-202.
5. Nagaev I, Smith U. Insulin resistance and type 2 diabetes are not related to resistin expression in human fat cells or skeletal muscle. Biochem Biophys Res Commun 2001;285:561-4.
6. Patel L, Buckels AC, Kinghorn IJ, Murdock PR, Holbrook JD, Plumpton C, et al. Resistin is expressed in human macrophages and directly regulated by PPAR gamma activators. Biochem Biophys Res Commun 2003;300:472-6.
7. Verma S, Li SH, Wang CH, Fedak PW, Li RK, Weisel RD, et al. Resistin promotes endothelial cell activation: further evidence of adipokine-endothelial interaction. Circulation 2003;108:736-40.
8. Kawanami D, Maemura K, Takeda N, Harada T, Nojiri T, Imai Y, et al. Direct reciprocal effects of resistin and adiponectin on vascular endothelial cells: a new insight into adipocytokine-endothelial cell interactions. Biochem Biophys Res Commun 2004;314:415-9.
9. Holcomb IN, Kabakoff RC, Chan B, Baker TW, Gurney A, Henzel W, et al. FIZZ1, a novel cysteine-rich secreted protein associated with pulmonary inflammation, defines a new gene family. EMBO J 2000;19:4046-55.
10. Gomez-Ambrosi J, Fruhbeck G. Do resistin and resistin-like molecules also link obesity to inflammatory diseases? Ann Intern Med 2001;135:306-7.
11. Burnett MS, Lee CW, Kinnaird TD, Stabile E, Durrani S, Dullum MK, et al. The potential role of resistin in atherogenesis. Atherosclerosis 2005;182:241-8.
12. Ohmori R, Momiyama Y, Kato R, Taniguchi H, Ogura M, Ayaori M, et al. Associations between serum resistin levels and insulin resistance, inflammation, and coronary artery disease. J Am Coll Cardiol 2005;46:379-80.
13. Burnett MS, Devaney JM, Adenika RJ, Lindsay R, Howard BV. Cross-sectional associations of resistin, coronary heart disease, and insulin resistance. J Clin Endocrinol Metab 2006;91:64-8.
14. Pischon T, Bamberger CM, Kratzsch J, Zyriax BC, Algenstaedt P, Boeing H, et al. Association of plasma resistin levels with coronary heart disease in women. Obes Res 2005;13:1764-71.
15. Fleiss J. Reliability of measurement. In: Fleiss JL, editor. The design and analysis of clinical experiments. New York: Wiley and Sons, 1986:1-32.
16. Kroke A, Klipstein-Grobusch K, Voss S, Moseneder J, Thielecke F, Noack R, et al. Validation of a self-administered food-frequency questionnaire administered in the European Prospective Investigation into Cancer and Nutrition (EPIC) Study: comparison of energy, protein, and macronutrient intakes estimated with the doubly labeled water, urinary nitrogen, and repeated 24-h dietary recall methods. Am J Clin Nutr 1999;70:439-47.
17. Boeing H, Korfmann A, Bergmann MM. Recruitment procedures of EPIC-Germany. European Investigation into Cancer and Nutrition. Ann Nutr Metab 1999;43:205-15.
18. Klipstein-Grobusch K, Georg T, Boeing H. Interviewer variability in anthropometric measurements and estimates of body composition. Int J Epidemiol 1997;26(Suppl 1):S174-80.
19. Rosner B. Fundamentals of biostatistics. Pacific Grove, CA: Duxbury Thomson Learning, 2000:653.
20. Schaffler A, Buchler C, Muller-Ladner U, Herfarth H, Ehling A, Paul G, et al. Identification of variables influencing resistin serum levels in patients with type 1 and type 2 diabetes mellitus. Horm Metab Res 2004;36:702-7.
21. Shetty GK, Economides PA, Horton ES, Mantzoros CS, Veves A. Circulating adiponectin and resistin levels in relation to metabolic factors, inflammatory markers, and vascular reactivity in diabetic patients and subjects at risk for diabetes. Diabetes Care 2004;27:2450-7.
22. Lee JH, Chan JL, Yiannakouris N, Kontogianni M, Estrada E, Seip R, et al. Circulating resistin levels are not associated with obesity or insulin resistance in humans and are not regulated by fasting or leptin administration: cross-sectional and interventional studies in normal, insulin-resistant, and diabetic subjects. J Clin Endocrinol Metab 2003;88:4848-56.
23. Yannakoulia M, Yiannakouris N, Bluher S, Matalas AL, Klimis-Zacas D, Mantzoros CS. Body fat mass and macronutrient intake in relation to circulating soluble leptin receptor, free leptin index, adiponectin, and resistin concentrations in healthy humans. J Clin Endocrinol Metab 2003;88:1730-6.
24. Silha JV, Krsek M, Skrha JV, Sucharda P, Nyomba BL, Murphy LJ. Plasma resistin, adiponectin and leptin levels in lean and obese subjects: correlations with insulin resistance. Eur J Endocrinol 2003;149:331-5.
25. Utzschneider KM, Carr DB, Tong J, Wallace TM, Hull RL, Zraika S, et al. Resistin is not associated with insulin sensitivity or the metabolic syndrome in humans. Diabetologia 2005;48:2330-3.
26. Reilly MP, Lehrke M, Wolfe ML, Rohatgi A, Lazar MA, Rader DJ. Resistin is an inflammatory marker of atherosclerosis in humans. Circulation 2005;111:932-9.
27. Bo S, Gambino R, Pagani A, Guidi S, Gentile L, Cassader M, et al. Relationships between human serum resistin, inflammatory markers and insulin resistance. Int J Obes (Lond) 2005;29:1315-20.
28. Gruendel S, Weickert MO, Garcia AL, Wagner K, Pfeiffer AF, Harsch I, et al. Serum resistin increases in a postprandial state during liquid meal challenge test in healthy human subjects. J Endocrinol Invest 2006;29:RC27-30.